Industry Updates from the Field of Stem Cell Research and Regenerative Medicine in June 2019
October 2019
in “
Regenerative Medicine
”
TLDR In June 2019, the stem cell research field saw major progress, including new clinical trials, FDA approvals, and industry collaborations.
In June 2019, there were numerous advancements in stem cell research and regenerative medicine. Follica reported positive interim data from a study on male androgenetic alopecia, showing significant hair count improvement in 20 male participants. Minovia Therapeutics began a Phase I/II trial for Pearson syndrome with 7 pediatric patients, and the FDA granted several designations to their mitochondrial cell therapy. Triumvira Immunologics received approval for a Phase I/II study of TAC01-CD19, a T-cell therapy for B-cell malignancies. Kiadis Pharma acquired CytoSen Therapeutics to enhance cell-based cancer immunotherapy. GPB Scientific was awarded a $2.2 million NIH grant to improve cell separation technology, and InGeneron extended its Series D financing to $43 million for cell therapy programs. Additionally, various strategic collaborations, clinical trials, and regulatory designations were announced, reflecting significant progress in the field.
